llagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of the Biologic License Application (BLA) and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for commercialization of XIAFLEX(TM) in Europe and other territories.
More information about the Company may be found on its website at www.biospecifics.com.
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, our expected revenue growth, and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including the ability of our partner Auxilium to obtain regulatory approval of XIAFLEX(TM) in the United States for Dupuytren's disease and Peyronie's disease and the ability of Pfizer to obtain regulatory approval of XIAFLEX(TM) in its territory for these same indications, which will determine the amount of milestone, royalty and sublicense income payments we may receive; the amount of earn out payments we may receive from DFB Biotech Inc. and its affiliates; whether Auxilium exercises its option under our license agreement for additional indications; the pote
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE BioSpecifics Technologies Corp.|
Copyright©2009 PR Newswire.
All rights reserved
. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease2
. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results3
. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market4
. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference5
. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors6
. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease7
. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results8
. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering9
. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering10
. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan11
. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering